Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Core Viewpoint - Santhera Pharmaceuticals has received approval from Swissmedic for AGAMREE® (vamorolone) to treat Duchenne muscular dystrophy (DMD) in patients aged four and older, with a commercial launch anticipated in the second half of 2026 [2][3]. Company Overview - Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on developing innovative medicines for rare neuromuscular diseases with high unmet medical needs [8]. - The company has an exclusive license for AGAMREE® (vamorolone) from ReveraGen for all indications worldwide [8]. Product Details - AGAMREE is a novel drug that binds to the same receptor as glucocorticoids but modifies its downstream activity, potentially dissociating efficacy from steroid safety concerns [4]. - The drug has shown no growth restriction and no negative effects on bone metabolism, unlike traditional corticosteroids [6]. Clinical Study Results - In the pivotal Phase 2b VISION-DMD study, AGAMREE met the primary endpoint of Time to Stand (TTSTAND) velocity versus placebo (p=0.002) at 24 weeks and demonstrated a good safety and tolerability profile [5]. - Common side effects included cushingoid features, vomiting, weight increase, and irritability, generally of mild to moderate severity [5]. Market Context - There are over 200 individuals affected by DMD in Switzerland, with limited treatment options available [3]. - Following the Swissmedic approval, Santhera has been granted a 15-year exclusivity period under Swiss orphan drug status, retaining exclusive distribution rights for AGAMREE in Switzerland [3].